Want to join the conversation?
In 3Q15, upon regulatory approval for Strensiq and Kanuma, $587MM acquired IPR&D assets associated with Strensiq and $4.12Bil of acquired IPR&D assets associated with Kanuma were reclassified from acquired IPR&D to purchased technology. $ALXN has supply agreements with Lonza through 2028 for manufacture of Soliris and Strensiq.
Keep your eyes on $FLXN. This one could ascend rapidly. Great time to buy your favourite bio stocks. Make more $$$
$CRM on the pop today.. big bubble.
Slumping and down the drain... $HDSN. Flush out your holdings !
$KITE I am loving this one... really flying like a kite today :-)